SEER Stock Analysis
SE
Uncovered
Seer Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 164 full-time employees. The company went IPO on 2020-12-04. The firm is engaged in developing transformative products. The Company’s initial product, the Proteograph product suite leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. The Proteograph product suite is an integrated solution that is comprised of consumables, an automation instrument, and software. Its approach is based on engineered NPs that enable unbiased sampling of intact proteins across the dynamic range of the proteome, capturing a myriad of molecular information at the level of protein variants as well as protein-protein interactions (PPIs). The company is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The firm is initially focused on research applications for the Proteograph product Suite and are selling and marketing the Proteograph for research use only (RUO) eliminates the need for complex workflows required by other unbiased approaches.